Soleno Therapeutics Investors Seek Compensation After Losses

Got story updates? Submit your updates here. ›

A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) on behalf of investors who lost money after the biotech company's stock price declined. The lawsuit alleges that Soleno Therapeutics made misleading statements about its business and financial performance, leading to significant investor losses.

Why it matters

Soleno Therapeutics is a publicly traded biotech company focused on developing treatments for rare diseases. The class action lawsuit highlights the risks investors face when investing in speculative biotech stocks, where even small missteps or setbacks can lead to major stock price declines and substantial financial losses for shareholders.

The details

The lawsuit, filed by the law firm Robbins LLP, alleges that Soleno Therapeutics made false and misleading statements about the progress and prospects of its lead drug candidate, which is intended to treat a rare metabolic disorder. The lawsuit claims the company overstated the drug's efficacy and the likelihood of regulatory approval, causing the stock price to be artificially inflated. When the company later disclosed setbacks in the drug's development, the stock price plummeted, resulting in significant losses for investors.

• The class action lawsuit was filed on March 31, 2026.

What’s next

The lawsuit is currently in the early stages, and the court will determine whether it can proceed as a class action. If successful, the lawsuit could result in Soleno Therapeutics being required to pay damages to affected investors.